It has been established that high-risk NB patients with increased RNA signatures for activated NK cells and CD8+ T cells experience improved outcomes.10 This implies that agents that prevent down regulation of immune function in the tumor microenvironment could represent a strategy for overcoming resistance to immunotherapy in NB and other cancers. Here, CD8A is linked to neuroblastoma.